An open study has been carried out with 18 patients suffering from partial epilepsy for evaluating the antiepileptic effectiveness of denzimol (DNZ) a new anticonvulsant drug. To 14 of them, 6 to 55 years old, 10 male and 4 female, DNZ t.i.d. was added to conventional antiepileptic drugs (AEDs), while 4 patients were administered DNA t.i.d. in monotherapy. Depending on the control of seizures the daily dose of DNZ was progressively increased up to 20 mg/kg/die in politherapy patients and to 17 mg/kg/die in monotherapy patients. The DNZ treatment lasted 1 to 18 months. In almost 90% of patients DNZ reduced the number of seizures at least 50%. No side effects were observed at the used doses. In some cases the daily dose of AEDs was modified to maintain their plasma levels unchanged. DNZ showed an important interaction with CBZ: after the onset of DNZ therapy and after every increase of the dose CBZ plasma level markedly rose.
|Translated title of the contribution||Intermediate - term anticonvulsant efficacy of denzimol: Results of an open study|
|Number of pages||3|
|Journal||Bollettino - Lega Italiana contro l'Epilessia|
|Publication status||Published - 1984|
ASJC Scopus subject areas
- Clinical Neurology